265 results on '"Mueller, Claudius"'
Search Results
52. Protein biomarkers for subtyping breast cancer and implications for future research
53. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma
54. Abstract 3877: A new frontier for molecular profiling of neoplastic bone tissue
55. Chapter 22 - Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena
56. GENO-12CLONAL EVOLUTION AND GENOMIC DIVERSITY IN A PANEL GLIOBLASTOMA TUMORS, NEUROSPHERE CULTURES AND ORTHOTOPIC XENOGRAFTS
57. Abstract 1755: TORK/DNA-PK inhibitor CC-115 is effective as a single agent in a subset of glioblastoma patient-derived cancer stem cells and xenografts and potentiates temozolomide therapy
58. Use of CLIA accredited multi-omic platforms to correlate clinical significance of WES/WTS testing with functional protein/phosphoprotein drug target activity.
59. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells
60. Whole Proteome Analysis of Mouse Lymph Nodes in Cutaneous Anthrax
61. Abstract 3795: Cabozantinib affects multiple signaling pathways in glioblastoma and is effective in a subset of xenograft tumors
62. Abstract 1213: Comparing protein pathway activation mapping portraits between gliobastoma patient-matched primary tumor, xenografts and neurospheres: implications for precision medicine
63. The Role of IKKβ in Venezuelan Equine Encephalitis Virus Infection
64. Glioblastoma Cell Enrichment Is Critical for Analysis of Phosphorylated Drug Targets and Proteomic–Genomic Correlations
65. Abstract 5377: Profiling of aurora kinase signaling in microdissected gastric cancer samples indicates a significant increase in histone deacetylase 4 (HDAC4).
66. Abstract 4141: Tumor cell enrichment is critical for assessing cell signaling pathways in glioblastoma multiforme.
67. Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples
68. Assessing Candidate Serum Biomarkers for Alzheimer's Disease: A Longitudinal Study
69. Abstract 1265: Tissue is alive: Preserving phosphoproteins and tissue morphology in clinical trial samples
70. Altered Serum Iron and Copper Homeostasis Predicts Cognitive Decline in Mild Cognitive Impairment
71. Signaling pathway-based stratification of clear cell renal cell carcinoma.
72. One-Step Preservation of Phosphoproteins and Tissue Morphology at Room Temperature for Diagnostic and Research Specimens
73. Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival
74. The Heme Degradation Pathway is a Promising Serum Biomarker Source for the Early Detection of Alzheimer's Disease
75. Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study
76. Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability
77. Iron Regulatory Protein 2 is Involved in Brain Copper Homeostasis
78. Serial Susceptibility Weighted MRI Measures Brain Iron and Microbleeds in Dementia
79. P4‐187: Iron regulatory protein 2 is involved in brain copper homeostasis
80. P3‐015: Identification of serum biomarker candidates for Alzheimer's disease
81. O1-01-05: Brain microvascular fragility is a major cause of Alzheimer's disease
82. Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias
83. Longitudinal Metabolic and Cognitive Changes in Mild Cognitive Impairment Patients
84. Clinical outcomes of gynecologic tumor treatment correlate with ERK protein phosphorylation as measured by a CLIA-accredited phosphoprotein assay.
85. Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease
86. P3-367: Assessment of altered blood/brain iron metabolism as a risk factor for the development of Alzheimer's disease
87. P1-149: Increased levels of proinflammatory cytokines in mild cognitive impairment compared to healthy aged controls
88. P2-349: Analysis of metabolite levels and ratios in age matched controls, mild cognitive impairment, and Alzheimer's disease converters using 1 H magnetic resonance spectroscopy
89. P1-080: Susceptibility weighted imaging - validation of an innovative MR imaging technique for measuring brain iron
90. P3–188: Immunohistochemical localization of iron regulatory protein–2 in Alzheimer's disease hippocampus
91. Laser Capture Microdissection for Protein and NanoString RNA Analysis.
92. Reduction of Preanalytical Variability in Specimen Procurement for Molecular Profiling.
93. Brain microvascular fragility is a major cause of Alzheimer's disease
94. Iron regulatory protein 2 is involved in brain copper homeostasis
95. Identification of serum biomarker candidates for Alzheimer's disease
96. P2-349: Analysis of metabolite levels and ratios in age matched controls, mild cognitive impairment, and Alzheimer’s disease converters using 1H magnetic resonance spectroscopy
97. CABOZANTINIB IS EFFECTIVE IN A SUBSET OF XENOGRAFT GBM TUMORS AND AFFECTS MULTIPLE SIGNALING PATHWAYS.
98. P2-349: Analysis of metabolite levels and ratios in age matched controls, mild cognitive impairment, and Alzheimer’s disease converters using 1H magnetic resonance spectroscopy.
99. Impact of genomic background and developmental state on signaling pathways and response to therapy in glioblastoma patient-derived cells.
100. Clinical Utility of a Highly Sensitive Lateral Flow Immunoassay as determined by Titer Analysis for the Detection of anti-SARS-CoV-2 Antibodies at the Point-of-Care.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.